Eris Lifesciences Limited
Eris Lifesciences Limited (ERIS.NS) Stock Competitors & Peer Comparison
See (ERIS.NS) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ERIS.NS | ₹1,353.60 | +2.32% | 187.5B | 42.99 | ₹31.49 | N/A |
| SUNPHARMA.BO | ₹1,824.10 | +0.88% | 4.4T | 40.09 | ₹45.50 | +0.91% |
| SUNPHARMA.NS | ₹1,823.50 | +0.84% | 4.4T | 40.02 | ₹45.57 | +0.91% |
| DIVISLAB.NS | ₹6,619.50 | +1.80% | 1.8T | 70.69 | ₹93.64 | +0.46% |
| DIVISLAB.BO | ₹6,618.20 | +1.73% | 1.8T | 70.65 | ₹93.68 | +0.46% |
| TORNTPHARM.BO | ₹4,252.05 | +1.44% | 1.4T | 67.23 | ₹63.25 | +0.83% |
| TORNTPHARM.NS | ₹4,251.80 | +1.59% | 1.4T | 63.50 | ₹66.96 | +0.83% |
| LUPIN.BO | ₹2,350.95 | +2.05% | 1.1T | 24.91 | ₹94.37 | +0.52% |
| LUPIN.NS | ₹2,348.80 | +1.89% | 1.1T | 23.16 | ₹101.43 | +0.52% |
| DRREDDY.BO | ₹1,287.95 | -2.65% | 1.1T | 18.99 | ₹67.84 | +1.21% |
Stock Comparison
ERIS.NS vs SUNPHARMA.BO Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, SUNPHARMA.BO has a market cap of 4.4T. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while SUNPHARMA.BO trades at ₹1,824.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas SUNPHARMA.BO's P/E ratio is 40.09. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to SUNPHARMA.BO's ROE of +0.15%. Regarding short-term risk, ERIS.NS is more volatile compared to SUNPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ERIS.NS.Check SUNPHARMA.BO's competition here
ERIS.NS vs SUNPHARMA.NS Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, SUNPHARMA.NS has a market cap of 4.4T. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while SUNPHARMA.NS trades at ₹1,823.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas SUNPHARMA.NS's P/E ratio is 40.02. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to SUNPHARMA.NS's ROE of +0.15%. Regarding short-term risk, ERIS.NS is more volatile compared to SUNPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ERIS.NS.Check SUNPHARMA.NS's competition here
ERIS.NS vs DIVISLAB.NS Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, DIVISLAB.NS has a market cap of 1.8T. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while DIVISLAB.NS trades at ₹6,619.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas DIVISLAB.NS's P/E ratio is 70.69. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to DIVISLAB.NS's ROE of +0.17%. Regarding short-term risk, ERIS.NS is more volatile compared to DIVISLAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ERIS.NS.Check DIVISLAB.NS's competition here
ERIS.NS vs DIVISLAB.BO Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, DIVISLAB.BO has a market cap of 1.8T. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while DIVISLAB.BO trades at ₹6,618.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas DIVISLAB.BO's P/E ratio is 70.65. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to DIVISLAB.BO's ROE of +0.17%. Regarding short-term risk, ERIS.NS is more volatile compared to DIVISLAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ERIS.NS.Check DIVISLAB.BO's competition here
ERIS.NS vs TORNTPHARM.BO Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, TORNTPHARM.BO has a market cap of 1.4T. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while TORNTPHARM.BO trades at ₹4,252.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas TORNTPHARM.BO's P/E ratio is 67.23. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to TORNTPHARM.BO's ROE of +0.29%. Regarding short-term risk, ERIS.NS is more volatile compared to TORNTPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ERIS.NS.Check TORNTPHARM.BO's competition here
ERIS.NS vs TORNTPHARM.NS Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, TORNTPHARM.NS has a market cap of 1.4T. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while TORNTPHARM.NS trades at ₹4,251.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas TORNTPHARM.NS's P/E ratio is 63.50. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to TORNTPHARM.NS's ROE of +0.29%. Regarding short-term risk, ERIS.NS is more volatile compared to TORNTPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ERIS.NS.Check TORNTPHARM.NS's competition here
ERIS.NS vs LUPIN.BO Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, LUPIN.BO has a market cap of 1.1T. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while LUPIN.BO trades at ₹2,350.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas LUPIN.BO's P/E ratio is 24.91. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to LUPIN.BO's ROE of +0.27%. Regarding short-term risk, ERIS.NS is more volatile compared to LUPIN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ERIS.NS.Check LUPIN.BO's competition here
ERIS.NS vs LUPIN.NS Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, LUPIN.NS has a market cap of 1.1T. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while LUPIN.NS trades at ₹2,348.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas LUPIN.NS's P/E ratio is 23.16. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to LUPIN.NS's ROE of +0.27%. Regarding short-term risk, ERIS.NS is more volatile compared to LUPIN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ERIS.NS.Check LUPIN.NS's competition here
ERIS.NS vs DRREDDY.BO Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, DRREDDY.BO has a market cap of 1.1T. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while DRREDDY.BO trades at ₹1,287.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas DRREDDY.BO's P/E ratio is 18.99. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to DRREDDY.BO's ROE of +0.16%. Regarding short-term risk, ERIS.NS is less volatile compared to DRREDDY.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check DRREDDY.BO's competition here
ERIS.NS vs DRREDDY.NS Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, DRREDDY.NS has a market cap of 1.1T. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while DRREDDY.NS trades at ₹1,287.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas DRREDDY.NS's P/E ratio is 18.97. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to DRREDDY.NS's ROE of +0.16%. Regarding short-term risk, ERIS.NS is less volatile compared to DRREDDY.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check DRREDDY.NS's competition here
ERIS.NS vs MANKIND.BO Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, MANKIND.BO has a market cap of 933.2B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while MANKIND.BO trades at ₹2,260.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas MANKIND.BO's P/E ratio is 52.41. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to MANKIND.BO's ROE of +0.13%. Regarding short-term risk, ERIS.NS is more volatile compared to MANKIND.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ERIS.NS.Check MANKIND.BO's competition here
ERIS.NS vs MANKIND.NS Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, MANKIND.NS has a market cap of 932.1B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while MANKIND.NS trades at ₹2,257.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas MANKIND.NS's P/E ratio is 52.34. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to MANKIND.NS's ROE of +0.13%. Regarding short-term risk, ERIS.NS is more volatile compared to MANKIND.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ERIS.NS.Check MANKIND.NS's competition here
ERIS.NS vs ZYDUSLIFE.NS Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, ZYDUSLIFE.NS has a market cap of 908B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while ZYDUSLIFE.NS trades at ₹902.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas ZYDUSLIFE.NS's P/E ratio is 18.40. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to ZYDUSLIFE.NS's ROE of +0.20%. Regarding short-term risk, ERIS.NS is more volatile compared to ZYDUSLIFE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ERIS.NS.Check ZYDUSLIFE.NS's competition here
ERIS.NS vs ZYDUSLIFE.BO Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, ZYDUSLIFE.BO has a market cap of 907.3B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while ZYDUSLIFE.BO trades at ₹901.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas ZYDUSLIFE.BO's P/E ratio is 18.39. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to ZYDUSLIFE.BO's ROE of +0.20%. Regarding short-term risk, ERIS.NS is more volatile compared to ZYDUSLIFE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ERIS.NS.Check ZYDUSLIFE.BO's competition here
ERIS.NS vs AUROPHARMA.NS Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, AUROPHARMA.NS has a market cap of 799.2B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while AUROPHARMA.NS trades at ₹1,376.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas AUROPHARMA.NS's P/E ratio is 22.92. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to AUROPHARMA.NS's ROE of +0.11%. Regarding short-term risk, ERIS.NS is more volatile compared to AUROPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ERIS.NS.Check AUROPHARMA.NS's competition here
ERIS.NS vs AUROPHARMA.BO Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, AUROPHARMA.BO has a market cap of 799.1B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while AUROPHARMA.BO trades at ₹1,375.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas AUROPHARMA.BO's P/E ratio is 23.36. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to AUROPHARMA.BO's ROE of +0.11%. Regarding short-term risk, ERIS.NS is more volatile compared to AUROPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ERIS.NS.Check AUROPHARMA.BO's competition here
ERIS.NS vs GLENMARK.NS Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, GLENMARK.NS has a market cap of 675.5B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while GLENMARK.NS trades at ₹2,393.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas GLENMARK.NS's P/E ratio is 63.36. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to GLENMARK.NS's ROE of +0.12%. Regarding short-term risk, ERIS.NS is more volatile compared to GLENMARK.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ERIS.NS.Check GLENMARK.NS's competition here
ERIS.NS vs GLENMARK.BO Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, GLENMARK.BO has a market cap of 675.2B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while GLENMARK.BO trades at ₹2,392.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas GLENMARK.BO's P/E ratio is 63.35. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to GLENMARK.BO's ROE of +0.12%. Regarding short-term risk, ERIS.NS is less volatile compared to GLENMARK.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check GLENMARK.BO's competition here
ERIS.NS vs ALKEM.NS Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, ALKEM.NS has a market cap of 640.9B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while ALKEM.NS trades at ₹5,360.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas ALKEM.NS's P/E ratio is 27.05. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to ALKEM.NS's ROE of +0.19%. Regarding short-term risk, ERIS.NS is more volatile compared to ALKEM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ERIS.NS.Check ALKEM.NS's competition here
ERIS.NS vs ALKEM.BO Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, ALKEM.BO has a market cap of 640.3B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while ALKEM.BO trades at ₹5,355.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas ALKEM.BO's P/E ratio is 27.00. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to ALKEM.BO's ROE of +0.19%. Regarding short-term risk, ERIS.NS is more volatile compared to ALKEM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ERIS.NS.Check ALKEM.BO's competition here
ERIS.NS vs LAURUSLABS.BO Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, LAURUSLABS.BO has a market cap of 629.7B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while LAURUSLABS.BO trades at ₹1,166.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas LAURUSLABS.BO's P/E ratio is 74.73. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to LAURUSLABS.BO's ROE of +0.19%. Regarding short-term risk, ERIS.NS is less volatile compared to LAURUSLABS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check LAURUSLABS.BO's competition here
ERIS.NS vs LAURUSLABS.NS Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, LAURUSLABS.NS has a market cap of 629.7B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while LAURUSLABS.NS trades at ₹1,166.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas LAURUSLABS.NS's P/E ratio is 74.63. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to LAURUSLABS.NS's ROE of +0.19%. Regarding short-term risk, ERIS.NS is less volatile compared to LAURUSLABS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check LAURUSLABS.NS's competition here
ERIS.NS vs SUVENPHAR.NS Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, SUVENPHAR.NS has a market cap of 412.4B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while SUVENPHAR.NS trades at ₹1,078.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas SUVENPHAR.NS's P/E ratio is 98.90. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to SUVENPHAR.NS's ROE of +0.09%. Regarding short-term risk, ERIS.NS is less volatile compared to SUVENPHAR.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check SUVENPHAR.NS's competition here
ERIS.NS vs SUVENPHAR.BO Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, SUVENPHAR.BO has a market cap of 411.4B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while SUVENPHAR.BO trades at ₹1,075.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas SUVENPHAR.BO's P/E ratio is 98.29. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to SUVENPHAR.BO's ROE of +0.07%. Regarding short-term risk, ERIS.NS is less volatile compared to SUVENPHAR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check SUVENPHAR.BO's competition here
ERIS.NS vs IPCALAB.BO Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, IPCALAB.BO has a market cap of 388.3B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while IPCALAB.BO trades at ₹1,530.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas IPCALAB.BO's P/E ratio is 42.72. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to IPCALAB.BO's ROE of +0.12%. Regarding short-term risk, ERIS.NS is less volatile compared to IPCALAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check IPCALAB.BO's competition here
ERIS.NS vs IPCALAB.NS Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, IPCALAB.NS has a market cap of 388.2B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while IPCALAB.NS trades at ₹1,530.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas IPCALAB.NS's P/E ratio is 42.71. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to IPCALAB.NS's ROE of +0.12%. Regarding short-term risk, ERIS.NS is less volatile compared to IPCALAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check IPCALAB.NS's competition here
ERIS.NS vs AJANTPHARM.BO Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, AJANTPHARM.BO has a market cap of 362.8B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while AJANTPHARM.BO trades at ₹2,904.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas AJANTPHARM.BO's P/E ratio is 35.81. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to AJANTPHARM.BO's ROE of +0.26%. Regarding short-term risk, ERIS.NS is less volatile compared to AJANTPHARM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check AJANTPHARM.BO's competition here
ERIS.NS vs AJANTPHARM.NS Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, AJANTPHARM.NS has a market cap of 362.4B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while AJANTPHARM.NS trades at ₹2,900.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas AJANTPHARM.NS's P/E ratio is 35.68. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to AJANTPHARM.NS's ROE of +0.26%. Regarding short-term risk, ERIS.NS is more volatile compared to AJANTPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ERIS.NS.Check AJANTPHARM.NS's competition here
ERIS.NS vs EMCURE.NS Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, EMCURE.NS has a market cap of 340B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while EMCURE.NS trades at ₹1,793.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas EMCURE.NS's P/E ratio is 39.09. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to EMCURE.NS's ROE of +0.19%. Regarding short-term risk, ERIS.NS is less volatile compared to EMCURE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check EMCURE.NS's competition here
ERIS.NS vs JBCHEPHARM.NS Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, JBCHEPHARM.NS has a market cap of 334.3B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while JBCHEPHARM.NS trades at ₹2,082.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas JBCHEPHARM.NS's P/E ratio is 43.92. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to JBCHEPHARM.NS's ROE of +0.22%. Regarding short-term risk, ERIS.NS is more volatile compared to JBCHEPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ERIS.NS.Check JBCHEPHARM.NS's competition here
ERIS.NS vs JBCHEPHARM.BO Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, JBCHEPHARM.BO has a market cap of 333.7B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while JBCHEPHARM.BO trades at ₹2,078.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas JBCHEPHARM.BO's P/E ratio is 43.74. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to JBCHEPHARM.BO's ROE of +0.22%. Regarding short-term risk, ERIS.NS is less volatile compared to JBCHEPHARM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check JBCHEPHARM.BO's competition here
ERIS.NS vs PEL.NS Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, PEL.NS has a market cap of 254.9B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while PEL.NS trades at ₹1,124.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas PEL.NS's P/E ratio is 44.24. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to PEL.NS's ROE of +0.02%. Regarding short-term risk, ERIS.NS is less volatile compared to PEL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check PEL.NS's competition here
ERIS.NS vs WOCKPHARMA.BO Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, WOCKPHARMA.BO has a market cap of 231.6B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while WOCKPHARMA.BO trades at ₹1,425.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas WOCKPHARMA.BO's P/E ratio is 1131.35. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to WOCKPHARMA.BO's ROE of +0.01%. Regarding short-term risk, ERIS.NS is more volatile compared to WOCKPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ERIS.NS.Check WOCKPHARMA.BO's competition here
ERIS.NS vs WOCKPHARMA.NS Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, WOCKPHARMA.NS has a market cap of 231.6B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while WOCKPHARMA.NS trades at ₹1,425.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas WOCKPHARMA.NS's P/E ratio is 1130.95. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to WOCKPHARMA.NS's ROE of +0.01%. Regarding short-term risk, ERIS.NS is less volatile compared to WOCKPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check WOCKPHARMA.NS's competition here
ERIS.NS vs PPLPHARMA.BO Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, PPLPHARMA.BO has a market cap of 212.1B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while PPLPHARMA.BO trades at ₹160.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas PPLPHARMA.BO's P/E ratio is -65.16. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to PPLPHARMA.BO's ROE of -0.04%. Regarding short-term risk, ERIS.NS is less volatile compared to PPLPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check PPLPHARMA.BO's competition here
ERIS.NS vs NEULANDLAB.BO Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, NEULANDLAB.BO has a market cap of 207B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while NEULANDLAB.BO trades at ₹16,135.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas NEULANDLAB.BO's P/E ratio is 115.68. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to NEULANDLAB.BO's ROE of +0.12%. Regarding short-term risk, ERIS.NS is less volatile compared to NEULANDLAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check NEULANDLAB.BO's competition here
ERIS.NS vs NEULANDLAB.NS Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, NEULANDLAB.NS has a market cap of 206.9B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while NEULANDLAB.NS trades at ₹16,124.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas NEULANDLAB.NS's P/E ratio is 115.56. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to NEULANDLAB.NS's ROE of +0.12%. Regarding short-term risk, ERIS.NS is less volatile compared to NEULANDLAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check NEULANDLAB.NS's competition here
ERIS.NS vs ASTRAZEN.BO Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, ASTRAZEN.BO has a market cap of 201.2B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while ASTRAZEN.BO trades at ₹8,046.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas ASTRAZEN.BO's P/E ratio is 99.92. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to ASTRAZEN.BO's ROE of +0.27%. Regarding short-term risk, ERIS.NS is less volatile compared to ASTRAZEN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check ASTRAZEN.BO's competition here
ERIS.NS vs ASTRAZEN.NS Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, ASTRAZEN.NS has a market cap of 201.2B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while ASTRAZEN.NS trades at ₹8,046.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas ASTRAZEN.NS's P/E ratio is 99.96. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to ASTRAZEN.NS's ROE of +0.27%. Regarding short-term risk, ERIS.NS is less volatile compared to ASTRAZEN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check ASTRAZEN.NS's competition here
ERIS.NS vs NATCOPHARM.NS Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, NATCOPHARM.NS has a market cap of 199.6B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while NATCOPHARM.NS trades at ₹1,114.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas NATCOPHARM.NS's P/E ratio is 12.83. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to NATCOPHARM.NS's ROE of +0.20%. Regarding short-term risk, ERIS.NS is less volatile compared to NATCOPHARM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check NATCOPHARM.NS's competition here
ERIS.NS vs NATCOPHARM.BO Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, NATCOPHARM.BO has a market cap of 199.5B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while NATCOPHARM.BO trades at ₹1,113.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas NATCOPHARM.BO's P/E ratio is 12.96. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to NATCOPHARM.BO's ROE of +0.20%. Regarding short-term risk, ERIS.NS is less volatile compared to NATCOPHARM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check NATCOPHARM.BO's competition here
ERIS.NS vs ERIS.BO Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, ERIS.BO has a market cap of 187.6B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while ERIS.BO trades at ₹1,354.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas ERIS.BO's P/E ratio is 42.84. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to ERIS.BO's ROE of +0.14%. Regarding short-term risk, ERIS.NS is less volatile compared to ERIS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check ERIS.BO's competition here
ERIS.NS vs COHANCE.NS Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, COHANCE.NS has a market cap of 180.1B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while COHANCE.NS trades at ₹470.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas COHANCE.NS's P/E ratio is 92.85. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to COHANCE.NS's ROE of +0.09%. Regarding short-term risk, ERIS.NS is less volatile compared to COHANCE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check COHANCE.NS's competition here
ERIS.NS vs COHANCE.BO Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, COHANCE.BO has a market cap of 179.8B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while COHANCE.BO trades at ₹469.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas COHANCE.BO's P/E ratio is 92.69. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to COHANCE.BO's ROE of +0.09%. Regarding short-term risk, ERIS.NS is less volatile compared to COHANCE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check COHANCE.BO's competition here
ERIS.NS vs GRANULES.NS Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, GRANULES.NS has a market cap of 174.3B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while GRANULES.NS trades at ₹703.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas GRANULES.NS's P/E ratio is 28.72. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to GRANULES.NS's ROE of +0.14%. Regarding short-term risk, ERIS.NS is less volatile compared to GRANULES.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check GRANULES.NS's competition here
ERIS.NS vs GRANULES.BO Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, GRANULES.BO has a market cap of 170.7B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while GRANULES.BO trades at ₹703.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas GRANULES.BO's P/E ratio is 31.28. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to GRANULES.BO's ROE of +0.14%. Regarding short-term risk, ERIS.NS is less volatile compared to GRANULES.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check GRANULES.BO's competition here
ERIS.NS vs APLLTD.NS Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, APLLTD.NS has a market cap of 150.5B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while APLLTD.NS trades at ₹765.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas APLLTD.NS's P/E ratio is 23.86. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to APLLTD.NS's ROE of +0.12%. Regarding short-term risk, ERIS.NS is more volatile compared to APLLTD.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ERIS.NS.Check APLLTD.NS's competition here
ERIS.NS vs APLLTD.BO Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, APLLTD.BO has a market cap of 150.4B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while APLLTD.BO trades at ₹764.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas APLLTD.BO's P/E ratio is 23.85. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to APLLTD.BO's ROE of +0.12%. Regarding short-term risk, ERIS.NS is more volatile compared to APLLTD.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ERIS.NS.Check APLLTD.BO's competition here
ERIS.NS vs JUBLPHARMA.NS Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, JUBLPHARMA.NS has a market cap of 147.5B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while JUBLPHARMA.NS trades at ₹931.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas JUBLPHARMA.NS's P/E ratio is 34.19. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to JUBLPHARMA.NS's ROE of +0.07%. Regarding short-term risk, ERIS.NS is more volatile compared to JUBLPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ERIS.NS.Check JUBLPHARMA.NS's competition here
ERIS.NS vs JUBLPHARMA.BO Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, JUBLPHARMA.BO has a market cap of 147.4B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while JUBLPHARMA.BO trades at ₹930.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas JUBLPHARMA.BO's P/E ratio is 34.14. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to JUBLPHARMA.BO's ROE of +0.07%. Regarding short-term risk, ERIS.NS is more volatile compared to JUBLPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ERIS.NS.Check JUBLPHARMA.BO's competition here
ERIS.NS vs GLS.NS Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, GLS.NS has a market cap of 133.1B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while GLS.NS trades at ₹1,086.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas GLS.NS's P/E ratio is 31.50. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to GLS.NS's ROE of +0.21%. Regarding short-term risk, ERIS.NS is less volatile compared to GLS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check GLS.NS's competition here
ERIS.NS vs GLS.BO Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, GLS.BO has a market cap of 133B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while GLS.BO trades at ₹1,085.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas GLS.BO's P/E ratio is 30.23. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to GLS.BO's ROE of +0.09%. Regarding short-term risk, ERIS.NS is less volatile compared to GLS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check GLS.BO's competition here
ERIS.NS vs CAPLIPOINT.NS Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, CAPLIPOINT.NS has a market cap of 132B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while CAPLIPOINT.NS trades at ₹1,736.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas CAPLIPOINT.NS's P/E ratio is 21.57. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to CAPLIPOINT.NS's ROE of +0.21%. Regarding short-term risk, ERIS.NS is less volatile compared to CAPLIPOINT.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check CAPLIPOINT.NS's competition here
ERIS.NS vs CAPLIPOINT.BO Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, CAPLIPOINT.BO has a market cap of 131.9B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while CAPLIPOINT.BO trades at ₹1,735.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas CAPLIPOINT.BO's P/E ratio is 21.55. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to CAPLIPOINT.BO's ROE of +0.21%. Regarding short-term risk, ERIS.NS is less volatile compared to CAPLIPOINT.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check CAPLIPOINT.BO's competition here
ERIS.NS vs ALIVUS.NS Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, ALIVUS.NS has a market cap of 131.2B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while ALIVUS.NS trades at ₹1,069.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas ALIVUS.NS's P/E ratio is 24.17. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to ALIVUS.NS's ROE of +0.19%. Regarding short-term risk, ERIS.NS is less volatile compared to ALIVUS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check ALIVUS.NS's competition here
ERIS.NS vs ALIVUS.BO Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, ALIVUS.BO has a market cap of 131.1B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while ALIVUS.BO trades at ₹1,067.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas ALIVUS.BO's P/E ratio is 24.16. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to ALIVUS.BO's ROE of +0.21%. Regarding short-term risk, ERIS.NS is less volatile compared to ALIVUS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check ALIVUS.BO's competition here
ERIS.NS vs CAPPL.BO Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, CAPPL.BO has a market cap of 109.4B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while CAPPL.BO trades at ₹1,446.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas CAPPL.BO's P/E ratio is 50.30. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to CAPPL.BO's ROE of +0.10%. Regarding short-term risk, ERIS.NS is less volatile compared to CAPPL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check CAPPL.BO's competition here
ERIS.NS vs STAR.NS Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, STAR.NS has a market cap of 95.1B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while STAR.NS trades at ₹1,031.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas STAR.NS's P/E ratio is 18.60. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to STAR.NS's ROE of +0.20%. Regarding short-term risk, ERIS.NS is less volatile compared to STAR.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check STAR.NS's competition here
ERIS.NS vs STAR.BO Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, STAR.BO has a market cap of 95.1B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while STAR.BO trades at ₹1,031.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas STAR.BO's P/E ratio is 18.60. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to STAR.BO's ROE of +0.20%. Regarding short-term risk, ERIS.NS is less volatile compared to STAR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check STAR.BO's competition here
ERIS.NS vs VIYASH.NS Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, VIYASH.NS has a market cap of 89.4B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while VIYASH.NS trades at ₹204.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas VIYASH.NS's P/E ratio is 79.07. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to VIYASH.NS's ROE of +0.10%. Regarding short-term risk, ERIS.NS is more volatile compared to VIYASH.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ERIS.NS.Check VIYASH.NS's competition here
ERIS.NS vs AKUMS.NS Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, AKUMS.NS has a market cap of 85.6B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while AKUMS.NS trades at ₹559.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas AKUMS.NS's P/E ratio is 26.74. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to AKUMS.NS's ROE of +0.10%. Regarding short-term risk, ERIS.NS is less volatile compared to AKUMS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check AKUMS.NS's competition here
ERIS.NS vs PGHL.NS Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, PGHL.NS has a market cap of 85.5B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while PGHL.NS trades at ₹5,151.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas PGHL.NS's P/E ratio is 36.17. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to PGHL.NS's ROE of +0.51%. Regarding short-term risk, ERIS.NS is more volatile compared to PGHL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ERIS.NS.Check PGHL.NS's competition here
ERIS.NS vs PGHL.BO Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, PGHL.BO has a market cap of 85.5B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while PGHL.BO trades at ₹5,150.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas PGHL.BO's P/E ratio is 36.19. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to PGHL.BO's ROE of +0.51%. Regarding short-term risk, ERIS.NS is more volatile compared to PGHL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ERIS.NS.Check PGHL.BO's competition here
ERIS.NS vs SHILPAMED.NS Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, SHILPAMED.NS has a market cap of 81.9B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while SHILPAMED.NS trades at ₹418.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas SHILPAMED.NS's P/E ratio is 37.05. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to SHILPAMED.NS's ROE of +0.06%. Regarding short-term risk, ERIS.NS is less volatile compared to SHILPAMED.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check SHILPAMED.NS's competition here
ERIS.NS vs SUDEEPPHRM.NS Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, SUDEEPPHRM.NS has a market cap of 77.9B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while SUDEEPPHRM.NS trades at ₹689.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas SUDEEPPHRM.NS's P/E ratio is 46.43. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to SUDEEPPHRM.NS's ROE of N/A. Regarding short-term risk, ERIS.NS is less volatile compared to SUDEEPPHRM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check SUDEEPPHRM.NS's competition here
ERIS.NS vs AARTIPHARM.NS Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, AARTIPHARM.NS has a market cap of 73.1B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while AARTIPHARM.NS trades at ₹806.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas AARTIPHARM.NS's P/E ratio is 34.24. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to AARTIPHARM.NS's ROE of +0.11%. Regarding short-term risk, ERIS.NS is less volatile compared to AARTIPHARM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check AARTIPHARM.NS's competition here
ERIS.NS vs AARTIPHARM.BO Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, AARTIPHARM.BO has a market cap of 73B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while AARTIPHARM.BO trades at ₹805.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas AARTIPHARM.BO's P/E ratio is 34.15. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to AARTIPHARM.BO's ROE of +0.11%. Regarding short-term risk, ERIS.NS is less volatile compared to AARTIPHARM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check AARTIPHARM.BO's competition here
ERIS.NS vs FDC.BO Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, FDC.BO has a market cap of 60.6B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while FDC.BO trades at ₹372.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas FDC.BO's P/E ratio is 27.95. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to FDC.BO's ROE of +0.09%. Regarding short-term risk, ERIS.NS is less volatile compared to FDC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check FDC.BO's competition here
ERIS.NS vs FDC.NS Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, FDC.NS has a market cap of 60.5B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while FDC.NS trades at ₹371.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas FDC.NS's P/E ratio is 27.96. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to FDC.NS's ROE of +0.09%. Regarding short-term risk, ERIS.NS is less volatile compared to FDC.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check FDC.NS's competition here
ERIS.NS vs SEQUENT.BO Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, SEQUENT.BO has a market cap of 50.6B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while SEQUENT.BO trades at ₹202.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas SEQUENT.BO's P/E ratio is 123.41. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to SEQUENT.BO's ROE of +0.06%. Regarding short-term risk, ERIS.NS is less volatile compared to SEQUENT.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check SEQUENT.BO's competition here
ERIS.NS vs SEQUENT.NS Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, SEQUENT.NS has a market cap of 50.6B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while SEQUENT.NS trades at ₹202.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas SEQUENT.NS's P/E ratio is 124.17. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to SEQUENT.NS's ROE of +0.06%. Regarding short-term risk, ERIS.NS is less volatile compared to SEQUENT.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check SEQUENT.NS's competition here
ERIS.NS vs SUVEN.BO Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, SUVEN.BO has a market cap of 49.3B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while SUVEN.BO trades at ₹212.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas SUVEN.BO's P/E ratio is -17.28. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to SUVEN.BO's ROE of -1.58%. Regarding short-term risk, ERIS.NS is less volatile compared to SUVEN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check SUVEN.BO's competition here
ERIS.NS vs INNOVACAP.NS Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, INNOVACAP.NS has a market cap of 48.3B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while INNOVACAP.NS trades at ₹844.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas INNOVACAP.NS's P/E ratio is 36.46. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to INNOVACAP.NS's ROE of +0.14%. Regarding short-term risk, ERIS.NS is less volatile compared to INNOVACAP.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check INNOVACAP.NS's competition here
ERIS.NS vs SUVEN.NS Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, SUVEN.NS has a market cap of 47.6B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while SUVEN.NS trades at ₹212.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas SUVEN.NS's P/E ratio is -17.26. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to SUVEN.NS's ROE of -1.58%. Regarding short-term risk, ERIS.NS is less volatile compared to SUVEN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check SUVEN.NS's competition here
ERIS.NS vs SPARC.BO Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, SPARC.BO has a market cap of 45.4B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while SPARC.BO trades at ₹139.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas SPARC.BO's P/E ratio is -16.92. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to SPARC.BO's ROE of +1.25%. Regarding short-term risk, ERIS.NS is less volatile compared to SPARC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check SPARC.BO's competition here
ERIS.NS vs SPARC.NS Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, SPARC.NS has a market cap of 45.3B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while SPARC.NS trades at ₹139.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas SPARC.NS's P/E ratio is -16.93. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to SPARC.NS's ROE of +1.25%. Regarding short-term risk, ERIS.NS is less volatile compared to SPARC.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check SPARC.NS's competition here
ERIS.NS vs SHILPAMED.BO Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, SHILPAMED.BO has a market cap of 40.9B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while SHILPAMED.BO trades at ₹418.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas SHILPAMED.BO's P/E ratio is 37.02. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to SHILPAMED.BO's ROE of +0.06%. Regarding short-term risk, ERIS.NS is less volatile compared to SHILPAMED.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check SHILPAMED.BO's competition here
ERIS.NS vs GUJTHEM.NS Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, GUJTHEM.NS has a market cap of 40.6B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while GUJTHEM.NS trades at ₹372.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas GUJTHEM.NS's P/E ratio is 84.61. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to GUJTHEM.NS's ROE of +0.19%. Regarding short-term risk, ERIS.NS is less volatile compared to GUJTHEM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check GUJTHEM.NS's competition here
ERIS.NS vs RPGLIFE.BO Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, RPGLIFE.BO has a market cap of 40.1B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while RPGLIFE.BO trades at ₹2,423.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas RPGLIFE.BO's P/E ratio is 19.79. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to RPGLIFE.BO's ROE of +0.41%. Regarding short-term risk, ERIS.NS is less volatile compared to RPGLIFE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check RPGLIFE.BO's competition here
ERIS.NS vs RPGLIFE.NS Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, RPGLIFE.NS has a market cap of 40B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while RPGLIFE.NS trades at ₹2,417.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas RPGLIFE.NS's P/E ratio is 19.72. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to RPGLIFE.NS's ROE of +0.41%. Regarding short-term risk, ERIS.NS is less volatile compared to RPGLIFE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check RPGLIFE.NS's competition here
ERIS.NS vs AARTIDRUGS.NS Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, AARTIDRUGS.NS has a market cap of 36.1B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while AARTIDRUGS.NS trades at ₹395.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas AARTIDRUGS.NS's P/E ratio is 17.89. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to AARTIDRUGS.NS's ROE of +0.15%. Regarding short-term risk, ERIS.NS is less volatile compared to AARTIDRUGS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check AARTIDRUGS.NS's competition here
ERIS.NS vs AARTIDRUGS.BO Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, AARTIDRUGS.BO has a market cap of 36B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while AARTIDRUGS.BO trades at ₹394.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas AARTIDRUGS.BO's P/E ratio is 17.84. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to AARTIDRUGS.BO's ROE of +0.15%. Regarding short-term risk, ERIS.NS is less volatile compared to AARTIDRUGS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check AARTIDRUGS.BO's competition here
ERIS.NS vs ORCHPHARMA.NS Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, ORCHPHARMA.NS has a market cap of 31.9B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while ORCHPHARMA.NS trades at ₹629.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas ORCHPHARMA.NS's P/E ratio is 167.79. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to ORCHPHARMA.NS's ROE of +0.01%. Regarding short-term risk, ERIS.NS is less volatile compared to ORCHPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check ORCHPHARMA.NS's competition here
ERIS.NS vs ORCHPHARMA.BO Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, ORCHPHARMA.BO has a market cap of 31.9B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while ORCHPHARMA.BO trades at ₹628.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas ORCHPHARMA.BO's P/E ratio is 166.82. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to ORCHPHARMA.BO's ROE of +0.00%. Regarding short-term risk, ERIS.NS is less volatile compared to ORCHPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check ORCHPHARMA.BO's competition here
ERIS.NS vs GUFICBIO.BO Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, GUFICBIO.BO has a market cap of 29.3B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while GUFICBIO.BO trades at ₹292.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas GUFICBIO.BO's P/E ratio is 58.59. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to GUFICBIO.BO's ROE of +0.08%. Regarding short-term risk, ERIS.NS is less volatile compared to GUFICBIO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check GUFICBIO.BO's competition here
ERIS.NS vs GUFICBIO.NS Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, GUFICBIO.NS has a market cap of 29.3B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while GUFICBIO.NS trades at ₹292.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas GUFICBIO.NS's P/E ratio is 58.68. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to GUFICBIO.NS's ROE of +0.08%. Regarding short-term risk, ERIS.NS is less volatile compared to GUFICBIO.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check GUFICBIO.NS's competition here
ERIS.NS vs BLISSGVS.BO Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, BLISSGVS.BO has a market cap of 29B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while BLISSGVS.BO trades at ₹274.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas BLISSGVS.BO's P/E ratio is 26.93. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to BLISSGVS.BO's ROE of +0.10%. Regarding short-term risk, ERIS.NS is less volatile compared to BLISSGVS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check BLISSGVS.BO's competition here
ERIS.NS vs BLISSGVS.NS Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, BLISSGVS.NS has a market cap of 29B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while BLISSGVS.NS trades at ₹274.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas BLISSGVS.NS's P/E ratio is 26.93. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to BLISSGVS.NS's ROE of +0.10%. Regarding short-term risk, ERIS.NS is less volatile compared to BLISSGVS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check BLISSGVS.NS's competition here
ERIS.NS vs IOLCP.NS Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, IOLCP.NS has a market cap of 27.9B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while IOLCP.NS trades at ₹94.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas IOLCP.NS's P/E ratio is 24.05. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to IOLCP.NS's ROE of +0.07%. Regarding short-term risk, ERIS.NS is less volatile compared to IOLCP.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check IOLCP.NS's competition here
ERIS.NS vs IOLCP.BO Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, IOLCP.BO has a market cap of 27.9B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while IOLCP.BO trades at ₹94.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas IOLCP.BO's P/E ratio is 24.04. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to IOLCP.BO's ROE of +0.07%. Regarding short-term risk, ERIS.NS is less volatile compared to IOLCP.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check IOLCP.BO's competition here
ERIS.NS vs UNICHEMLAB.BO Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, UNICHEMLAB.BO has a market cap of 27.1B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while UNICHEMLAB.BO trades at ₹385.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas UNICHEMLAB.BO's P/E ratio is 9.23. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to UNICHEMLAB.BO's ROE of +0.12%. Regarding short-term risk, ERIS.NS is less volatile compared to UNICHEMLAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check UNICHEMLAB.BO's competition here
ERIS.NS vs UNICHEMLAB.NS Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, UNICHEMLAB.NS has a market cap of 27.1B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while UNICHEMLAB.NS trades at ₹385.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas UNICHEMLAB.NS's P/E ratio is 9.21. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to UNICHEMLAB.NS's ROE of +0.12%. Regarding short-term risk, ERIS.NS is less volatile compared to UNICHEMLAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check UNICHEMLAB.NS's competition here
ERIS.NS vs NOVARTIND.NS Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, NOVARTIND.NS has a market cap of 25.3B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while NOVARTIND.NS trades at ₹1,026.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas NOVARTIND.NS's P/E ratio is 26.07. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to NOVARTIND.NS's ROE of +0.13%. Regarding short-term risk, ERIS.NS is less volatile compared to NOVARTIND.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check NOVARTIND.NS's competition here
ERIS.NS vs NOVARTIND.BO Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, NOVARTIND.BO has a market cap of 25.2B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while NOVARTIND.BO trades at ₹1,021.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas NOVARTIND.BO's P/E ratio is 25.97. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to NOVARTIND.BO's ROE of +0.13%. Regarding short-term risk, ERIS.NS is more volatile compared to NOVARTIND.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ERIS.NS.Check NOVARTIND.BO's competition here
ERIS.NS vs SOLARA.NS Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, SOLARA.NS has a market cap of 25B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while SOLARA.NS trades at ₹518.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas SOLARA.NS's P/E ratio is -107.89. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to SOLARA.NS's ROE of -0.02%. Regarding short-term risk, ERIS.NS is less volatile compared to SOLARA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check SOLARA.NS's competition here
ERIS.NS vs SOLARA.BO Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, SOLARA.BO has a market cap of 25B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while SOLARA.BO trades at ₹518.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas SOLARA.BO's P/E ratio is -108.23. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to SOLARA.BO's ROE of -0.02%. Regarding short-term risk, ERIS.NS is less volatile compared to SOLARA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check SOLARA.BO's competition here
ERIS.NS vs HIKAL.NS Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, HIKAL.NS has a market cap of 24B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while HIKAL.NS trades at ₹194.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas HIKAL.NS's P/E ratio is -183.70. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to HIKAL.NS's ROE of -0.01%. Regarding short-term risk, ERIS.NS is less volatile compared to HIKAL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check HIKAL.NS's competition here
ERIS.NS vs HIKAL.BO Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, HIKAL.BO has a market cap of 24B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while HIKAL.BO trades at ₹194.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas HIKAL.BO's P/E ratio is 243.31. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to HIKAL.BO's ROE of -0.01%. Regarding short-term risk, ERIS.NS is less volatile compared to HIKAL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ERIS.NS.Check HIKAL.BO's competition here
ERIS.NS vs ALEMBICLTD.NS Comparison May 2026
ERIS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ERIS.NS stands at 187.5B. In comparison, ALEMBICLTD.NS has a market cap of 23.5B. Regarding current trading prices, ERIS.NS is priced at ₹1,353.60, while ALEMBICLTD.NS trades at ₹91.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ERIS.NS currently has a P/E ratio of 42.99, whereas ALEMBICLTD.NS's P/E ratio is 7.37. In terms of profitability, ERIS.NS's ROE is +0.14%, compared to ALEMBICLTD.NS's ROE of +0.13%. Regarding short-term risk, ERIS.NS is more volatile compared to ALEMBICLTD.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ERIS.NS.Check ALEMBICLTD.NS's competition here